MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 406972 | Name: RKI-1313
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RKI-1313 is a negative control for RKI-1447 (GLXC-05200), a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.

Chemical Structure

RKI-1313
RKI-1313
CAS#1342276-76-9

Theoretical Analysis

MedKoo Cat#: 406972

Name: RKI-1313

CAS#: 1342276-76-9

Chemical Formula: C17H16N4O2S

Exact Mass: 340.0994

Molecular Weight: 340.40

Elemental Analysis: C, 59.98; H, 4.74; N, 16.46; O, 9.40; S, 9.42

Price and Availability

Size Price Availability Quantity
5mg USD 300.00 2 Weeks
10mg USD 500.00 2 Weeks
25mg USD 850.00 2 Weeks
100mg USD 1,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
RKI-1313; RKI 1313; RKI1313.
IUPAC/Chemical Name
1-(3-Methoxybenzyl)-3-[4-(pyridin-4-yl)thiazol-2-yl]urea
InChi Key
BDCUKYUIVYKXCQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H16N4O2S/c1-23-14-4-2-3-12(9-14)10-19-16(22)21-17-20-15(11-24-17)13-5-7-18-8-6-13/h2-9,11H,10H2,1H3,(H2,19,20,21,22)
SMILES Code
O=C(NC1=NC(C2=CC=NC=C2)=CS1)NCC3=CC=CC(OC)=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
RKI-1313 is an inhibitor of Rho-associated kinase 1 (ROCK1) and 2 (IC50s = 34 and 8 µM, respectively).
In vitro activity:
To be determined
In vivo activity:
Compared to RKI-1447, RKI-1313 was a much weaker analog in vitro, had little effect on the phosphorylation levels of ROCK substrates, migration, invasion or anchorage-independent growth. Reference: Cancer Res. 2012 Oct 1;72(19):5025-34. https://pubmed.ncbi.nlm.nih.gov/22846914/

Preparing Stock Solutions

The following data is based on the product molecular weight 340.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP, Schönbrunn E, Lawrence NJ, Sebti SM. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012 Oct 1;72(19):5025-34. doi: 10.1158/0008-5472.CAN-12-0954. Epub 2012 Jul 30. PMID: 22846914; PMCID: PMC3463757.
In vitro protocol:
To be determined
In vivo protocol:
1. Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP, Schönbrunn E, Lawrence NJ, Sebti SM. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012 Oct 1;72(19):5025-34. doi: 10.1158/0008-5472.CAN-12-0954. Epub 2012 Jul 30. PMID: 22846914; PMCID: PMC3463757.
1: Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP, Schönbrunn E, Lawrence NJ, Sebti SM. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012 Oct 1;72(19):5025-34. doi: 10.1158/0008-5472.CAN-12-0954. PubMed PMID: 22846914; PubMed Central PMCID: PMC3463757.